Akebia Therapeutics Inc.

Akebia Therapeutics believes that the shorter circulating half-life of its oral daily HIF-regulating compound, currently in Phase I trials, will keep it from over-stimulating EPO production, which is related to the cardiovascular and other safety issues faced by current injectable ESAs. Beyond its efforts with HIF and anemia, Akebia is also pursuing preclinical research on inhibitors of the human protein tyrosine phosphatase beta for vascular leakage.

10151 Carver Road

Suite 205

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip